Pomide 2mg (Pomalidomide)

Request Price

Boxed warning: pomalidomide can cause severe, life-threatening birth defects and must never be taken during pregnancy. It also raises the risk of blood clots in the veins and arteries, including deep vein thrombosis, pulmonary embolism, heart attack and stroke. Use only under an oncologist’s supervision, with pregnancy testing, contraception and clot prevention as described below.

What our medical expert told about Pomalidomide

“Pomalidomide is the immunomodulatory drug I turn to when myeloma has progressed after both lenalidomide and a proteasome inhibitor such as bortezomib. It still works in many patients whose disease no longer responds to lenalidomide. The main trade-offs are low neutrophil counts with a higher risk of infection, and blood clots, so every patient needs a clot-prevention plan from day one. Before starting, I check a full blood count, liver and kidney function, and clot risk. Women who could become pregnant need two negative pregnancy tests first. I also ask about ciprofloxacin, fluvoxamine and smoking, because they change pomalidomide levels.”

Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center

Clinical Uses & Safety Management Protocols

Pomide 2mg is a generic Pomalyst alternative containing pomalidomide, manufactured by Beacon Pharmaceuticals PLC in Bangladesh. Pomalidomide is an oral immunomodulatory drug (IMiD) and a thalidomide analogue. It is the third drug in the class after thalidomide and lenalidomide.

Pomide is a prescription-only oncology medicine. It should be started and monitored by a hematologist or oncologist experienced in treating multiple myeloma.

Pomalidomide is used for relapsed or refractory multiple myeloma, after the disease has progressed on earlier treatment. In the US label it is given with dexamethasone to adults who have already received at least two therapies, including lenalidomide and a proteasome inhibitor. In Europe it is also approved with bortezomib and dexamethasone after at least one prior regimen that included lenalidomide.

Three safety steps run through every course of treatment. Pregnancy must be ruled out and prevented, because pomalidomide causes birth defects. Patients receive clot prevention, such as aspirin or an anticoagulant chosen by risk. Blood counts are checked weekly for the first 8 weeks and monthly after that. Pomalidomide is taken on days 1 to 21 of each 28-day cycle and continues until the disease progresses.

Precise Indications & Biomarker Necessity

The current US prescribing information (revised February 2025) lists pomalidomide for two conditions. Beacon lists Pomide for relapsed or refractory multiple myeloma.

Multiple myeloma. In combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease progressed on or within 60 days of completing the last therapy. This indication has full FDA approval, granted in April 2015 after the MM-003 trial confirmed the 2013 accelerated approval.

European label. The EU product information also approves pomalidomide with bortezomib and dexamethasone for adults with multiple myeloma who have received at least one prior regimen that included lenalidomide. This triplet (PVd) is not part of the US label.

Kaposi sarcoma. For adults with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), and for adults with Kaposi sarcoma who are HIV-negative. This is an accelerated approval from May 2020, based on overall response rate, and continued approval may depend on confirmatory trials. Patients with HIV continue HAART during treatment. The usual Kaposi sarcoma dose is 5 mg, which the Beacon 2 mg capsule cannot provide.

Tests needed before starting. Pomalidomide does not require a genomic biomarker. The prescriber confirms progression with myeloma markers (serum and urine M-protein, serum free light chains) and documents the prior lenalidomide and proteasome inhibitor treatment. Baseline tests include a full blood count, liver function, kidney function and a clot-risk assessment. Women of reproductive potential need two negative pregnancy tests before the first dose.

The Pomalyst label lists no separate limitation-of-use statement. It does advise against adding pembrolizumab to a thalidomide analogue and dexamethasone outside controlled trials, because two randomized trials showed higher mortality.

Mechanism & Pharmacokinetics (ADME)

Mechanism of action. Pomalidomide binds cereblon, part of a cullin ring E3 ubiquitin ligase complex inside the cell. This tags two transcription factors, Ikaros and Aiolos, for breakdown. Myeloma cells depend on these proteins, so their loss slows growth and triggers cell death. Pomalidomide also boosts T-cell and natural killer cell activity, blocks new blood vessel formation, and lowers TNF-α and IL-6 production by monocytes. In laboratory studies it worked together with dexamethasone, including in lenalidomide-resistant myeloma cell lines.

Absorption. Peak plasma levels are reached 2 to 3 hours after a dose. A high-fat, high-calorie meal delays the peak by about 2.5 hours, lowers peak levels by about 27% and lowers total exposure by about 8%. These changes are small, so the label allows dosing with or without food. At 4 mg daily in multiple myeloma, steady-state exposure averages 860 ng·h/mL, with a peak of 75 ng/mL.

Distribution. The apparent volume of distribution is 62 to 138 L. Plasma protein binding is low, at 12% to 44%. Pomalidomide is a P-glycoprotein (P-gp) substrate.

Metabolism. Pomalidomide is metabolized mainly in the liver by CYP1A2 and CYP3A4, with minor roles for CYP2C19 and CYP2D6. CYP1A2 is the main route, which is why strong CYP1A2 inhibitors and smoking change exposure more than CYP3A4 drugs do.

Elimination. The half-life is about 9.5 hours in healthy volunteers and about 7.5 hours in patients with multiple myeloma. Apparent clearance is 7 to 10 L/h. After a radiolabeled dose, about 73% was recovered in urine and 15% in feces. Only about 2% (urine) and 8% (feces) was unchanged drug. Hemodialysis removes pomalidomide, which is why patients on dialysis take their dose after the session.

Dosage & Adverse Event (AE) Management

Starting dose (multiple myeloma). 4 mg by mouth once daily on days 1 to 21 of each 28-day cycle, with dexamethasone, until the disease progresses. With Pomide 2mg, the 4 mg dose is two capsules taken together. In the MM-003 trial, dexamethasone was 40 mg once daily on days 1, 8, 15 and 22 (20 mg for patients over 75). Capsules are swallowed whole with water and should not be opened, broken or chewed. They can be taken with or without food.

Starting each cycle. A new cycle begins only when the absolute neutrophil count (ANC) is at least 500/mcL and platelets are at least 50,000/mcL.

Dose reduction. The multiple myeloma ladder is 4 mg, then 3 mg, 2 mg and 1 mg. Pomalidomide is stopped permanently if the patient cannot tolerate 1 mg.

  • ANC below 500/mcL or febrile neutropenia: withhold, check blood counts weekly, and restart 1 mg lower once ANC is at least 500/mcL.
  • Platelets below 25,000/mcL: withhold, check blood counts weekly, and restart 1 mg lower once platelets are at least 50,000/mcL.
  • Other Grade 3 or 4 toxicity: withhold, and restart 1 mg lower once it improves to Grade 2 or below, at the prescriber’s discretion.

Discontinuation triggers. Stop permanently for angioedema, anaphylaxis, Grade 4 rash, skin peeling or blistering, or any other severe skin reaction.

Strong CYP1A2 inhibitors. Avoid them. If one cannot be avoided, reduce pomalidomide to 2 mg (one Pomide capsule).

Renal impairment. Severe renal impairment requiring dialysis: 3 mg daily for multiple myeloma, taken after dialysis on dialysis days. Kaposi sarcoma: 4 mg daily.

Hepatic impairment. Multiple myeloma: 3 mg daily for mild or moderate impairment (Child-Pugh A or B) and 2 mg daily for severe impairment (Child-Pugh C). Kaposi sarcoma: 3 mg daily for any degree of impairment.

Kaposi sarcoma dosing. 5 mg once daily on days 1 to 21 of each 28-day cycle, with HAART continued in patients with HIV. The blood-count thresholds for holding and restarting treatment differ from the multiple myeloma rules.

Strength availability in Bangladesh. Beacon makes only the 2 mg capsule. The table shows which label doses it can deliver. The prescriber should know before starting that a 3 mg or 1 mg reduction would need a different source.

Label doseWhen it is usedWith Pomide 2mg
4 mgMultiple myeloma starting doseYes, two capsules
3 mgFirst dose reduction; dialysis; mild or moderate liver impairmentNo 3 mg option
2 mgSecond dose reduction; strong CYP1A2 inhibitor; severe liver impairmentYes, one capsule
1 mgThird dose reductionNo 1 mg option
5 mgKaposi sarcoma starting doseNo 5 mg option

Adverse reactions in multiple myeloma. The label lists the most common adverse reactions (≥30%) as fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper respiratory tract infections, back pain and pyrexia. The MM-003 table (Trial 2 in the label) shows reactions occurring in ≥5% of patients on pomalidomide with low-dose dexamethasone and at least 2% more often than with high-dose dexamethasone. Grade 3/4 rows use ≥1% with at least a 1% difference.

Adverse reactionAll grades, POM + LD-Dex vs HD-DexGrade 3/4, POM + LD-Dex vs HD-Dex
Neutropenia51% vs 21%48% vs 16%
Fatigue and asthenia47% vs 43%9% vs 12%
Upper respiratory tract infection31% vs 13%3% vs <1%
Pyrexia27% vs 23%3% vs 5%
Dyspnea25% vs 17%6% vs 5%
Constipation22% vs 15%2% vs 0%
Diarrhea22% vs 19%1% vs 1%
Back pain20% vs 16%5% vs 4%
Cough20% vs 10%<1% vs <1%
Pneumonia19% vs 13%16% vs 10%
Peripheral neuropathy17% vs 12%2% vs 1%
Febrile neutropenia9% vs 0%9% vs 0%

Discontinuation and dose changes. In MM-003, adverse reactions led to permanent discontinuation in 8% of patients. Dose interruptions were needed in 67% and dose reductions in 27%.

Adverse reactions in Kaposi sarcoma. In the 28-patient trial, the most common adverse reactions (≥20%) were rash (71%), constipation (71%), fatigue (68%), nausea (36%), diarrhea (32%), and cough, dyspnea, peripheral edema and upper respiratory tract infection (29% each). Serious adverse reactions occurred in 18%, and 11% stopped treatment permanently.

Drug-Drug Interaction (DDI) Matrix

Pomalidomide is cleared mainly by CYP1A2, with CYP3A4 as a second route, and it is a P-gp substrate. CYP1A2 is the interaction that changes dosing. A full medication review, including antibiotics and antidepressants, is needed before starting Pomide.

Interacting agent classExamplesEffect on pomalidomideRecommended action
Strong CYP1A2 inhibitorsCiprofloxacin, fluvoxamine (named in the label)Fluvoxamine raised pomalidomide exposure (AUC) by 125%Avoid; if unavoidable, reduce pomalidomide to 2 mg and monitor closely
Strong CYP1A2 inhibitor plus strong CYP3A4/P-gp inhibitorFluvoxamine with ketoconazole (studied)AUC rose 146%Avoid; if unavoidable, reduce pomalidomide to 2 mg
Strong CYP3A4 and P-gp inhibitors aloneKetoconazole (studied)AUC rose 19%No dose change in the label
Strong CYP3A4 inducersCarbamazepine (studied)AUC fell 20%No dose change in the label
CYP1A2 inducersNot named in the labelNot studied; may lower exposurePrescriber to review each case
Cigarette smoking25 cigarettes a day (studied)AUC fell 32%; peak level rose 14%Tell patients that smoking may reduce the effect of pomalidomide
DexamethasoneGiven with pomalidomide in the label regimenNo clinically significant changeUsed together as labeled
PembrolizumabWith a thalidomide analogue and dexamethasoneHigher mortality in two randomized trialsNot recommended outside controlled trials
FoodHigh-fat, high-calorie mealPeak level down about 27%, AUC down about 8%Take with or without food

The examples other than the studied drugs are the label’s named examples. The prescriber or pharmacist should check every other medicine individually.

Clinical Efficacy & Real-World Data

Two trials on the US label support pomalidomide in multiple myeloma, and a third supports the European triplet with bortezomib. The figures for MM-002 and MM-003 are from Section 14 of the current US label.

MM-002 (Trial 1, phase 2). 221 patients with relapsed and refractory myeloma, previously treated with lenalidomide and bortezomib, were randomized to pomalidomide alone or with low-dose dexamethasone. The overall response rate was 29.2% with dexamethasone vs 7.4% without it, and the median duration of response with dexamethasone was 7.4 months. This trial supported the 2013 accelerated approval and set dexamethasone as the standard partner.

MM-003 (Trial 2, phase 3). 455 patients were randomized 2:1 to pomalidomide plus low-dose dexamethasone or to high-dose dexamethasone alone. In the pomalidomide arm, 94% were refractory to lenalidomide and 74% to both lenalidomide and bortezomib. Median progression-free survival, the primary endpoint, was 3.6 months vs 1.8 months (HR 0.45; 95% CI 0.35-0.59; p<0.001). Median overall survival was 12.4 months vs 8.0 months (HR 0.70; 95% CI 0.54-0.92; p=0.009). With longer follow-up, the published analysis reported median PFS of 4.0 vs 1.9 months, median OS of 13.1 vs 8.1 months, and response rates of 32% vs 11%.

OPTIMISMM (phase 3, pomalidomide with bortezomib). 559 patients who had received 1 to 3 prior regimens, all including lenalidomide, were randomized to pomalidomide, bortezomib and dexamethasone (PVd) or to bortezomib and dexamethasone. About 70% were refractory to lenalidomide. Median progression-free survival was 11.2 months vs 7.1 months (HR 0.61; p<0.0001). Grade 3/4 neutropenia occurred in 42% vs 9% and Grade 3/4 infections in 31% vs 18%. This trial is the basis of the EU approval of PVd.

Kaposi sarcoma (NCI trial 12-C-0047). 28 patients (18 with HIV, 10 without) received pomalidomide 5 mg. The overall response rate was 71% (67% with HIV, 80% without), including 14% complete responses. The median duration of response was 12.1 months.

Caveats. MM-003 compared pomalidomide with high-dose dexamethasone, a weak control by current standards, and 53% of control patients later received pomalidomide, which narrows the survival difference. In the US, pomalidomide triplets with daratumumab, isatuximab or elotuzumab are approved on those antibodies’ own labels. No trial has compared the pomalidomide triplets with each other head to head.

Pomide vs Revlixen vs Thalimide

All three are thalidomide-class immunomodulatory drugs with the same pregnancy controls, but they are used at different stages of myeloma and follow different dosing and clearance rules. Data are from each originator’s current US label.

FeaturePomide (pomalidomide)Revlixen (lenalidomide)Thalimide (thalidomide)
OriginatorPomalystRevlimidThalomid
Myeloma setting in the US labelAfter at least two prior therapies, including lenalidomide and a proteasome inhibitorNewly diagnosed and previously treated myeloma; maintenance after stem cell transplantNewly diagnosed myeloma
Standard myeloma dose4 mg once daily, days 1-21 of 28, with dexamethasone25 mg once daily, days 1-21 of 28, with dexamethasone; 10 mg daily for maintenance200 mg once daily in 28-day cycles, with dexamethasone
How to takeWith or without foodWith or without foodAt bedtime, at least 1 hour after the evening meal
Main clearanceLiver (CYP1A2, CYP3A4)Kidneys; starting dose set by creatinine clearanceHydrolysis; not a CYP450 substrate
Boxed warningEmbryo-fetal toxicity; venous and arterial thromboembolismEmbryo-fetal toxicity; hematologic toxicity; venous and arterial thromboembolismEmbryo-fetal toxicity; venous thromboembolism
Signature side effectNeutropenia and infectionsNeutropenia and thrombocytopeniaPeripheral neuropathy and drowsiness
Other US indicationsKaposi sarcomaMyelodysplastic syndrome with 5q deletion; mantle cell, follicular and marginal zone lymphomaErythema nodosum leprosum
Contraception window4 weeks before, during and 4 weeks after4 weeks before, during and 4 weeks after4 weeks before, during and 4 weeks after
Bangladeshi manufacturerBeacon (2 mg)Everest (10 mg, 25 mg)Beacon (50 mg, 100 mg)

Pomalidomide is the drug of this class used after lenalidomide stops working, and it is the only one of the three cleared mainly through CYP1A2. Lenalidomide is the only one whose starting dose depends on kidney function.

Precautions & Special Populations

Embryo-fetal toxicity: Pomalidomide is a thalidomide analogue and is contraindicated in pregnancy. Women of reproductive potential need two negative pregnancy tests before starting: the first 10 to 14 days before and the second within 24 hours before the prescription. Testing then continues weekly for the first 4 weeks, then monthly with regular cycles or every 2 weeks with irregular cycles. They must avoid pregnancy for 4 weeks before starting, during treatment and interruptions, and for 4 weeks after the last dose, using two reliable methods of contraception or continuous abstinence.

Male patients: Pomalidomide is present in semen. Men must use a latex or synthetic condom with any partner who could become pregnant, during treatment and for up to 4 weeks after stopping, even after a vasectomy. They must not donate sperm.

Blood donation: No patient should donate blood during treatment or for 4 weeks after the last dose.

Restricted distribution: In the US, pomalidomide is available only through the PS-Pomalidomide REMS program. That program does not cover personal import, so the treating physician carries responsibility for the same pregnancy testing, contraception counseling and capsule handling.

Venous and arterial thromboembolism: Deep vein thrombosis, pulmonary embolism, heart attack and stroke occur in patients with myeloma treated with pomalidomide. In MM-003, where anticoagulant therapy was mandated, thromboembolic events occurred in 8.0% of patients on pomalidomide with low-dose dexamethasone vs 3.3% on high-dose dexamethasone. Venous events occurred in 4.7% vs 1.3% and arterial events in 3.0% vs 1.3%. Thromboprophylaxis is recommended, chosen by the patient’s risk factors.

Hematologic toxicity: Across both myeloma trials, neutropenia of any grade occurred in 51% of patients, Grade 3 or 4 neutropenia in 46%, and febrile neutropenia in 8%. Blood counts are checked weekly for the first 8 weeks and monthly after that. In Kaposi sarcoma, Grade 3 or 4 neutropenia occurred in 50%, and counts are checked every 2 weeks for the first 12 weeks.

Hepatotoxicity: Hepatic failure, including fatal cases, has occurred. Liver tests are checked monthly. Pomalidomide is stopped if liver enzymes rise, and a lower dose may be considered once values return to baseline.

Severe cutaneous reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS have been reported and can be fatal. Treatment is interrupted for Grade 2 or 3 rash at the prescriber’s discretion, and stopped permanently for Grade 4, peeling or blistering rash, or suspected SJS, TEN or DRESS.

Dizziness and confusional state: Dizziness occurred in 14% and confusional state in 7% of patients in the myeloma trials. Patients should avoid driving or operating machinery if affected, and avoid other medicines that cause dizziness or confusion without medical advice.

Neuropathy: Neuropathy occurred in 18% of patients in MM-003, mostly peripheral (about 12%). Grade 3 neuropathy occurred in 2%, with no Grade 4 cases.

Second primary malignancies: Acute myelogenous leukemia has been reported in patients given pomalidomide as an investigational therapy outside multiple myeloma.

Tumor lysis syndrome: Patients with a high tumor burden before treatment are at highest risk and should be monitored closely.

Hypersensitivity: Angioedema and anaphylaxis have been reported, and pomalidomide is stopped permanently if either occurs. Patients with a past serious reaction to thalidomide or lenalidomide were excluded from the trials and may be at higher risk.

Lactation: No data exist on pomalidomide in human milk. Women should not breastfeed during treatment.

Renal impairment: Severe impairment requiring dialysis raised exposure by 38% and the serious adverse event rate by 64%. The dose is 3 mg for multiple myeloma (4 mg for Kaposi sarcoma), taken after dialysis on dialysis days. Pomide cannot provide the 3 mg dose.

Hepatic impairment: Multiple myeloma: 3 mg for Child-Pugh A or B, 2 mg for Child-Pugh C. Only the 2 mg dose can be given with Pomide.

Elderly patients: In the myeloma trials, 44% of patients were over 65 and 10% over 75. Patients over 65 had more pneumonia than younger patients.

Children: Safety and effectiveness have not been established in pediatric patients.

Global Access Guide and Quality Assurance

Pomide is manufactured by Beacon Pharmaceuticals PLC, a WHO-GMP certified Bangladeshi manufacturer. A facility’s WHO-GMP certification confirms the manufacturing process meets international quality standards. It is not the same as FDA approval of this generic product. Pomide is supplied for personal import under Named Patient Program frameworks where legally permitted; it is not FDA-approved.

Bioequivalence status. Pomalidomide is a small molecule, so a bioequivalence comparison with Pomalyst is possible in principle. Beacon has not yet supplied comparative dissolution or bioequivalence data for Pomide, so this page makes no bioequivalence claim. We will update this section if the data are provided.

Storage and handling. For reference, Pomalyst is stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C. Capsules should be kept in their original pack and never opened or crushed.

Beacon Pharmaceuticals PLC Manufacturing Insights

Beacon Pharmaceuticals PLC is a Dhaka-based manufacturer with a dedicated oncology portfolio, including Thalimide (thalidomide), Bortez (bortezomib) and Dasanix (dasatinib).

Global Access via Named Patient Program (NPP)

Patients outside Bangladesh can access Pomide through Named Patient Program and personal-import pathways where their country’s regulations allow it. The process runs in four steps.

  1. Upload the prescription. Send a valid prescription from a licensed hematologist or oncologist through the Upload Prescription page, or by WhatsApp (+8801792288474) or email (info@genericoncology.com).
  2. Receive a quote. Our team confirms stock, pack quantity and delivery timeline, and sends a written quote.
  3. Complete the documentation. We prepare the import documents your country requires, such as the prescription, invoice and batch documents. Some countries also need a permit or letter from the treating physician. For pomalidomide, the physician also confirms pregnancy testing and contraception counseling where they apply.
  4. Shipping with tracking. Pomide is dispatched by express courier with a tracking number, typically arriving in 7-14 days depending on region.

Import rules vary by country, and some countries restrict thalidomide-class medicines more tightly than other cancer drugs. Patients should confirm with their physician and local regulator that personal import of pomalidomide is permitted before ordering.

Pomide 2mg vs Pomalyst 2mg (Head-to-Head Comparison)

FeaturePomide 2mgPomalyst 2mg
Active ingredientPomalidomide 2 mgPomalidomide 2 mg
Dosage formOral capsuleOral hard capsule (dark blue cap, orange body, imprinted “POML”)
Strengths available2 mg only (pack of 18 capsules, 3 x 6)1 mg, 2 mg, 3 mg and 4 mg
Approved indicationsPer Beacon: relapsed or refractory multiple myelomaUS label: multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor (with dexamethasone); Kaposi sarcoma
Standard myeloma dose4 mg as two 2 mg capsules once daily, days 1-21 of 284 mg as one 4 mg capsule once daily, days 1-21 of 28
ManufacturerBeacon Pharmaceuticals PLC, BangladeshCelgene Corporation (Bristol Myers Squibb)
Regulatory statusWHO-GMP certified facility; not FDA-approved; supplied under NPP frameworksFDA-approved (accelerated approval 2013; full approval for myeloma 2015; Kaposi sarcoma accelerated approval 2020)
Bioequivalence dataNot yet supplied by BeaconReference product
StorageKeep below 30°C temperature, away from light & moisture. Keep out of the reach of children.20°C to 25°C

Both contain the same active ingredient at the same strength, and the myeloma regimen is the same. The differences are the manufacturer, the regulatory pathway, the bioequivalence data still to come from Beacon, and the strength range: Pomide comes only as 2 mg, so the 3 mg and 1 mg reductions are not available.

Frequently Asked Questions

What is the price of Pomide 2mg?

The price depends on the number of packs, destination country and shipping method. Contact us through the Upload Prescription page, WhatsApp (+8801792288474) or info@genericoncology.com for a current written quote.

Both contain pomalidomide, and the myeloma dose of 4 mg is the same. Pomide is made by Beacon Pharmaceuticals PLC in a WHO-GMP certified facility, while Pomalyst is made by Celgene (Bristol Myers Squibb) and is FDA-approved. Pomide is not FDA-approved, and Beacon has not yet supplied bioequivalence data.

No. A product called Pomide is also sold in India by Hetero, in 2 mg and 4 mg strengths. The Pomide on this page is Beacon’s 2 mg capsule, made in Bangladesh.

It binds a protein called cereblon inside myeloma cells, which leads to the breakdown of two proteins the cells need to survive. It also strengthens the immune system’s attack on the cancer. It is usually taken with dexamethasone.

No genetic test is required. Your doctor checks your blood counts, liver and kidney function, and your risk of blood clots. Women who could become pregnant need two negative pregnancy tests before the first dose and regular tests during treatment.

Take 4 mg (two capsules) once a day on days 1 to 21 of each 28-day cycle, or the dose your doctor prescribes. Swallow the capsules whole with water, with or without food. Do not open, break or chew them.

One pack holds 18 capsules. At 4 mg a day, one 28-day cycle uses 42 capsules, so each cycle needs two packs plus six capsules. At 2 mg a day, a cycle uses 21 capsules.

If it is less than 12 hours past your usual time, take it as soon as you remember. If more than 12 hours have passed, skip that dose and take the next one at the usual time. Do not take two doses to make up for a missed one.

Call right away for leg pain or swelling, chest pain, shortness of breath, sudden weakness or numbness, fever or chills, unusual bleeding or bruising, a blistering or peeling rash, or yellowing of the skin or eyes. Women should stop the medicine and call at once if they miss a period or think they may be pregnant.

Yes. This is the setting it is approved for. In the MM-003 tr ial, 94% of patients on pomalidomide were already refractory to lenalidomide, and pomalidomide with dexamethasone still lengthened progression-free and overall survival.